- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01686958
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral ultrasound therapy system. The technology is developed for patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
The treatment is conducted completely within an MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland, thereby reducing the risk of possible damage to important surrounding anatomy such as the rectum, urinary sphincters, neurovascular bundles and pelvic bone. This coagulation method, therefore, has the potential to have lower complication rates than conventional therapies.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- London Health Science Centre
-
-
-
-
-
Heidelberg, Germany, 69120
- German Cancer Research Center (DKFZ)
-
-
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- William Beaumont Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, age ≥65
- Patient with low-risk, early-stage organ-confined prostate cancer (Stage T1c or T2a, N0, M0).
- Gleason score 6 (3+3)
- Prostate-specific antigen (PSA) ≤ 10 ng/ml
- Eligible for MR imaging (DOC-10252)
Meets the following criteria on pre-treatment transrectal ultrasound imaging:
- No cysts or calcifications > 1.0 cm in size
- No evidence of extraprostatic extension or seminal vesicle invasion
- Overall prostate size less than 5 cm in sagittal length and less than 7 cm in diameter
- Biopsy confirmed adenocarcinoma of the prostate, performed at least 6 weeks prior to and no more than 6 months prior to the scheduled treatment.
- Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA)
- Normal rectal anatomy and rectal mucosa on digital rectal examination
Exclusion Criteria:
- Bleeding disorder
- Abnormal coagulation and current anticoagulant therapy.
- Acute or chronic Urinary Tract Infection
- Interest in future fertility
- History of allergy relevant medication or other
- History of any other malignancy other than skin cancer
- Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome
- Prior treatment of the prostate gland
- Prior treatment with 5 alpha reductase inhibitor allowed (not as prostate cancer treatment or prevention) as long as drug has been stopped for minimum 3 months
- History of any major rectal or pelvic surgery
- History of ulcerative colitis or other chronic inflammatory conditions affecting rectum
- History of documented clinical prostatitis requiring therapy within previous 6 months
- History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter
- Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic)
- Neurologic bladder disorders
- Untreated bladder stones
- History of acute urinary retention
- Confirmed or suspected bladder cancer
- Urinary sphincter abnormalities
- Active untreated gross hematuria for any cause
- Post Void Residual (PVR) bladder volume > 250 mL
- Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder
Additional exclusion criteria on file....
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MR-Guided Transurethral US Ablation
MR-Guided Transurethral US Ablation of Prostate Tissue
|
The technology is developed to treat patients with organ confined prostate cancer.
The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - Evaluate the Frequency of Treatment Related Adverse Events
Time Frame: 12 months from the Treatment Date
|
All reported adverse events were recorded.
The frequency was measured as the number of study participants who experienced a treatment/device related adverse event after receiving treatment delivery with PAD-105, the investigational device.
|
12 months from the Treatment Date
|
Safety - Evaluate the Severity of Treatment Related Adverse Events
Time Frame: 12 months from the Treatment Date
|
Severity of treatment/device related adverse events were evaluated in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) standard (version 4), published by the National Cancer Institute (NCI). There was no intraoperative complication, no rectal injury or fistula and no severe urinary incontinence. No Grade 4 (G4) or higher adverse events and only one attributable Grade 3 (G3) event; reported below. The common and significant Grade 1 (G1) and Grade 2 (G2) genitourinary events have also been reported. |
12 months from the Treatment Date
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility - Evaluate the Effectiveness of the Investigational System to Thermally Coagulate Prostate Tissue Conforming to the Target Volume With a High Degree of Accuracy and Precision
Time Frame: On Treatment Date
|
Conformal thermal coagulation of prostate tissue will be determined quantitatively using measures of targeting accuracy which compare the spatial difference between the target volume and target temperature isotherm determined from MR thermometry images acquired during treatment.
|
On Treatment Date
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Efficacy - Biopsy
Time Frame: 12 months from the Treatment Date
|
Evaluate the effectiveness of the treatment to achieve disease control at 12 months based on biopsy results.
|
12 months from the Treatment Date
|
Treatment Efficacy - PSA
Time Frame: As per the Study Schedule, measured at 1-month, 3-months, 6-months and 12-months from the Treatment Date compared to Baseline
|
Based on measurements obtained at each study visit, characterize the pattern of PSA response within the first 12 months following treatment in comparison to baseline.
|
As per the Study Schedule, measured at 1-month, 3-months, 6-months and 12-months from the Treatment Date compared to Baseline
|
Treatment Efficacy - Quality of Life - Urinary Symptoms
Time Frame: Baseline and 12-months post Treatment
|
Evaluate quality of life in the first 12 months following Treatment compared to Baseline, using a standardized questionnaire, International Prostate Symptom Score (IPSS), which focuses on urinary symptoms. Total Score: 0 - 35 0-7 - mildly symptomatic 8-19 - moderately symptomatic 20-35 - severely symptomatic |
Baseline and 12-months post Treatment
|
Treatment Efficacy - Quality of Life - Erectile Function
Time Frame: Baseline and 12-months post Treatment
|
Evaluate quality of life in the first 12 months following Treatment compared to Baseline, using a standardized questionnaire, Erectile Function EF domain of the International Index of Erectile Function (IIEF-15), which focuses on erectile symptoms. Minimum score value - 0 Maximum score value - 30 A higher score corresponds to a better outcome; lower score indicative of erectile dysfunction |
Baseline and 12-months post Treatment
|
Treatment Efficacy - Quality of Life - Bowel Habits
Time Frame: Baseline and 12-months post Treatment
|
Evaluate quality of life in the first 12 months following Treatment compared to Baseline, using a standardized questionnaire, Bowel Habits domain of the UCLA Prostate Cancer Index Short Form (UCLA-PCl-SF-BH), which focuses on bowel symptoms. Minimum score value - 0 Maximum score value - 100 A higher score corresponds to better outcome |
Baseline and 12-months post Treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joseph Chin, MD, London Health Science Center
- Principal Investigator: James Relle, MD, William Beaumont Hospitals
- Principal Investigator: Ryan Berglund, MD, The Cleveland Clinic
- Principal Investigator: Heinz P Schlemmer, MD, German Cancer Research Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DOC-10246
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on MR-Guided Transurethral US Ablation of Prostate Tissue
-
University Hospital, Strasbourg, FranceCompletedLocalized Prostate Cancer | MRI Guided Transurethral Ultrasound Ablation | Ablation TherapyFrance
-
Icahn School of Medicine at Mount SinaiPhilips HealthcareUnknownProstate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
Heinrich-Heine University, DuesseldorfCompletedProstate CancerGermany
-
Urological Research Network, LLCRecruitingCancer of the Prostate | Neoplasms ProstateUnited States
-
Ardeshir RastinehadPhilips HealthcareRecruitingProstate Cancer | Prostate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
TC Erciyes UniversityCompleted
-
Turku University HospitalUniversity of TurkuActive, not recruitingBenign Prostatic Hyperplasia | Locally Advanced Prostate Cancer | Locally Recurrent Prostate Cancer | Localised Prostate CancerFinland
-
Cedar, United KingdomNational Institute for Health and Care Excellence (NICE); British Society of... and other collaboratorsUnknownTransurethral Resection of the Prostate (TURP) | Lower Urinary Tract Symptoms Caused by Benign Prostatic Enlargement (LUTS BPE) | Prostate Artery Embolisation (PAE) | Open Prostatectomy | Laser Enucleation or Ablation of the Prostate
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingHealth Status Unknown | Elevated PSAUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingProstate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8United States